First published April 18, 2016.
Degarelix is a prostate-cancer drug that sharply lowers testosterone, and researchers in Sweden have tested it as a preventive treatment for men with paedophilic disorder who ask for help before they offend. In a 2020 randomised trial of 52 men, a single injection reduced two known risk factors for child sexual abuse, high sexual drive and sexual interest in children, within about two weeks. It is not a vaccine, it does not "cure" paedophilia, and no study has shown that it guarantees abuse will not happen.
Headlines in 2016 described the drug as a "paedophilia vaccine". Here is what the research actually set out to do, what it found, and why prevention-focused treatment matters.
What degarelix is and how it works
Degarelix, sold under the brand name Firmagon, is approved to treat advanced prostate cancer, a disease whose growth is fuelled by testosterone. It belongs to a class of drugs called GnRH antagonists. It blocks a hormone signal from the brain that tells the testes to make testosterone, so blood levels fall within hours to days. A single dose lasts around three months.
Testosterone is not the cause of paedophilia, but it strongly influences sex drive. Lowering it can make sexual urges less intense and easier to control. That is the logic behind using it in men who are attracted to children and want to avoid acting on it. Some 2016 reports also claimed the drug blocked "anger" centres in the brain; that is not how it works, and its effect is hormonal.
The 2016 pilot and the push for funding
The research is led by teams at the Karolinska Institutet in Stockholm, including psychiatrist Christoffer Rahm and andrologist Stefan Arver. In 2012 the team helped set up a national helpline, later known as PrevenTell, for people worried about their own sexual thoughts or behaviour. The volume of calls convinced them that many men with these attractions actively seek help. Arver put it this way: "We have the proof of principle that people with these worries really want help."
In early 2016, as reported by Reuters and the Telegraph, the team described a small pilot with five men recruited through the helpline. Their testosterone reportedly fell to undetectable levels within days, and their self-rated risk of offending dropped noticeably within two weeks. To run a proper trial the researchers needed money and turned to the science crowdfunding site Walacea, seeking about £38,000 for a project called Priotab (Paedophilia at Risk: Investigations of Treatment and Biomarkers). Part of the aim was also to look for biological markers that might help identify people at higher risk.
What the 2020 randomised trial found
The full study was published in JAMA Psychiatry in April 2020 by Valdemar Landgren, Kinda Malki, Matteo Bottai, Stefan Arver and Christoffer Rahm. According to the Karolinska Institutet's summary, 52 men with paedophilic disorder volunteered and were randomly assigned to receive either degarelix or a placebo injection, with neither they nor the researchers knowing who got which.
- Men given degarelix showed lower scores on two established risk factors for abuse: overall sexual desire and sexual attraction to children.
- The effect was measurable within two weeks of the injection.
- Many participants described feeling calmer and less preoccupied by sexual thoughts, and most wanted to continue the treatment after the study.
- Side effects included hot flushes and reactions at the injection site. Conclusions about mood effects were difficult because many participants were already depressed before the study.
Rahm described the results as "an important step towards an evidence-based treatment for pedophilic disorder". The trial measured risk factors, not actual offending, and it was small and short. The team said a follow-up study would examine longer-term effects and compare the drug with psychotherapy.
How this differs from "chemical castration"
Hormone-lowering drugs have been used for decades with convicted sex offenders, sometimes as a condition of release, a practice often called chemical castration. Older drugs such as cyproterone acetate and medroxyprogesterone can cause side effects including breast growth, weight gain and bone thinning, and long-term testosterone suppression of any kind carries a risk of osteoporosis.
The Swedish approach differs in timing and consent. It is offered voluntarily to people who have not necessarily committed any crime and who come forward because they want to stay safe. The medical literature is clear that such drugs reduce sex drive but do not change who a person is attracted to, so they are usually combined with psychological therapy rather than used alone.
What the statistics say, and what they don't
Numbers around this subject are often stretched. A 2015 UK National Crime Agency estimate, reported by the Telegraph, suggested that somewhere between one in 20 and one in 35 men may have some sexual interest in children. Clinical reviews are more cautious: the true prevalence of paedophilia is unknown, but most estimates put it below 5% of adult men.
Two further points are often missed. First, not everyone with paedophilic attractions abuses children, and many never do. Second, not everyone who abuses children is a paedophile: studies of detected offenders suggest only around a quarter to a half have a primary sexual interest in children, with others offending for reasons such as opportunity, power or other disorders. A drug aimed at paedophilic disorder can therefore address only part of the problem.
Research led by Karolinska and Oxford, reported in 2016, estimated that roughly 40% of the variation in the risk of sexual offending is linked to genetic factors, with the rest down to environment and life experience, including having been abused in childhood. That kind of finding describes risk across a population, not destiny for any individual. Reported UK figures at the time pointed to more than 36,000 recorded sexual offences against children in a single year, a reminder of why prevention research attracts attention.
Why prevention-focused treatment matters
Most child protection work starts after harm is done. Programmes like Sweden's PrevenTell and Germany's Dunkelfeld project try to reach people before that point, offering confidential therapy and, where appropriate, medication. Researchers argue that making help available, rather than only punishment after the fact, protects children by giving people at risk a realistic way to control their behaviour.
Anyone worried about their own thoughts towards children should talk to a doctor or contact a confidential prevention service in their country. Anyone worried about a child's safety should contact local child protection services or the police.
Sources: Karolinska Institutet: Drug reduces the risk of child sexual abuse (April 2020); Landgren et al., JAMA Psychiatry (2020); Wikipedia: Pedophilia; Reuters (April 2016); The Telegraph (April 2016); The Telegraph: NCA estimate (2015); Walacea: Priotab campaign; originally reported by AnonHQ.
COMMENTS